TEXAS CHILDREN'S HOSPITAL; THE HOUSTON METHODIST HOSPITAL.
Blood. 2014 Jun 19;123(25):3848-9. doi: 10.1182/blood-2014-05-570291.
In this issue of Blood, Bachanova et al describe how modulation of the inhibitory tumor environment may enhance natural killer (NK) cell clinical activity and produce encouraging results in the treatment of refractory acute myeloid leukemia (AML). NK cells are highly proliferative, early responders of the innate immune response that in preclinical models can exert potent activity against a wide range of malignancies, including AML, and across HLA barriers. Considerable efforts have been made to exploit this activity in clinical trials but with only modest success.
在本期《Blood》中，Bachanova 等人描述了如何调节抑制肿瘤的环境，以增强自然杀伤（NK）细胞的临床活性，并在治疗难治性急性髓系白血病（AML）方面取得令人鼓舞的结果。NK 细胞具有高度增殖性，是先天免疫反应的早期应答者，在临床前模型中可以对多种恶性肿瘤产生强大的活性，包括 AML，并且可以跨越 HLA 障碍。人们已经做出了相当大的努力来利用这种活性进行临床试验，但只有适度的成功。
